CG Oncology (CGON) Update / Briefing May 03, 2024 04:30 PM ET Speaker0 Welcome to the CG Oncology conference call to discuss updated results from the company's BOND-three Phase three clinical trial of Credo Stimogene for the treatment of high risk BCG unresponsive non muscle invasive bladder cancer. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a Q and A session. As a courtesy to others, we would ask participants to limit themselves to one qu ...